2-oxindole has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, C; Gong, X; Yang, Y; Zhang, L; Zhao, S; Zheng, Q; Zhou, H | 1 |
| Agalou, A; Argyros, O; Asvos, X; Beis, D; Davos, CH; Fokas, D; Karampelas, T; Papakyriakou, A; Tamvakopoulos, C; Varela, A | 1 |
2 other study(ies) available for 2-oxindole and Experimental Neoplasms
| Article | Year |
|---|---|
Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Indoles; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Structure-Activity Relationship; Sunitinib | 2014 |
Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Oxindoles; Pyrroles; Sunitinib; Tumor Burden; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |